bioAffinity Technologies CEO: Record CyPath Lung testing fuels growth ambitions

bioAffinity Technologies Inc (NASDAQ:BIAF) President and CEO Maria Zannes spoke with Proactive's Stephen Gunnion about record testing volumes for the company's CyPath Lung test, growing physician adoption and plans to expand its commercial reach.

The company performed 235 CyPath Lung tests in October, a monthly record and equivalent to approximately 45% of all tests conducted in the previous quarter.

Zannes said the increase reflected both new physicians adopting the non-invasive lung cancer test and greater use among existing customers. She highlighted the role of doctors sharing their experiences with colleagues in driving wider uptake.

The company is expanding its sales team, building relationships with patient advocacy groups and pursuing new distribution and healthcare partnerships, including opportunities to reach US veterans.

Zannes also discussed the importance of early lung cancer detection, drawing on her own family's experience of the disease.

Beyond CyPath Lung, bioAffinity is advancing research into diagnostic applications for asthma and chronic obstructive pulmonary disease (COPD), with the aim of bringing a product to market next year.

For more healthcare company interviews, medical technology updates and investor news, visit Proactive's YouTube channel. Don't forget to give this video a like, subscribe to the channel and enable notifications for future content.

Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy

#bioAffinityTechnologies #CyPathLung #LungCancerDetection #MariaZannes #LungCancer #EarlyCancerDetection #CancerDiagnostics #MedicalDiagnostics #HealthcareInnovation #MedTech #COPD #Asthma #PrecisionDiagnostics #HealthcareStocks #ProactiveInvestors